MedPath

Study On Effect Of Slidenafil in intrauterine growth restrictio

Phase 4
Completed
Conditions
Health Condition 1: O94- Sequelae of complication of pregnancy, childbirth, and the puerperiumHealth Condition 2: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium
Registration Number
CTRI/2019/01/017354
Lead Sponsor
I
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
200
Inclusion Criteria

Effective fetal weight less than 10 percentile for gestational age at 28 TO 29 weeks of pregnancy

Fetal abdominal circumference less than 5 Percentile for gestational age at 28 TO 29 weeks of pregnancy

Exclusion Criteria

Any Kind of fetal malformation

Congenital defects in foetus

Use of any other vasodilator agent by pregnant mother during the course of study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath